Nexus Pharmaceuticals, LLC

07/09/2025

Dan Geffen and Drew Barbone will be representing Nexus Pharmaceuticals at the GSHP Summer Meeting this weekend in Amelia Island, Florida! Stop by our booth to learn more about how Nexus can support your organization. See you there!

06/26/2025

Heading to the TPA Summer Meeting this week? Stop by and say hello to David Farris from Nexus Pharmaceuticals! He’ll be on-site to chat with new and familiar faces about our mission and how our products are making an impact across the country.

06/20/2025

Don't miss the chance to connect with Drew Barbone at ALSHP, June 22–24! Stop by Nexus' booth to discuss how we can help support your organization's needs.

05/28/2025

Nexus Pharmaceuticals is proud to share that on May 9, 2025, it won a patent litigation involving injectable cyclophosphamide.

“We are pleased that the district court judge issued a thoughtful opinion concluding that Ingenus’s patent was invalid,” said Chief Executive Officer and President, Usman Ahmed. “Nexus appreciates the judgment, and we look forward to helping patients access generic alternatives for injectable cyclophosphamide.”

Read the full press release here: https://bwnews.pr/4mBZzum

Nexus Wins Patent Litigation For Injectable Cyclophosphamide, Paving Way For Generic

05/22/2025

We are pleased to announce that Nexus Pharmaceuticals' Methylene Blue Injection is now available!

For detailed information, please read the full press release: https://bwnews.pr/43IU3i0

05/13/2025

Say hello to ease and efficiency – our Baclofen Injection Convenience Kits are designed to streamline your treatment process, ensuring patients get the care they need, when they need it. Order through your Wholesaler today! 👨‍⚕️👩‍⚕️

04/11/2025

Introducing the Baclofen Injection Refill Kit – a convenience kit aimed at enhancing patient care and optimizing healthcare processes. Read the full press release here: https://bwnews.pr/3G7Vldi

03/31/2025

"Nexus Pharmaceuticals Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL vial alongside Fluorescein Injection, USP 10% in a 5 mL vial." Read the full press release here: https://bwnews.pr/3E3rfa2

03/19/2025

We are very excited to be adding Tranexamic Acid to our product portfolio,” says Vince LoPiccolo, Vice President of Sales at Nexus. “Antifibrinolytic Agents, such as Tranexamic Acid, are crucial to have available in operating rooms and we are proud to contribute to the supply.” Read the full press release here: https://bwnews.pr/442QjIC

02/17/2025

We are excited to announce that Nexus' Fluorescein Injection is now available through our new partner, Hilco Vision. We are grateful that this partnership will enable access of Fluorescein to a wider network of healthcare providers.

02/13/2025

We are excited to announce the FDA approval of Nexus’ Tacrolimus Injection, the first and only available in a vial. Read the full press release here https://bwnews.pr/4gILLdj

01/21/2025

Meet Eleanor Oskorep! As QC Finished Product Lead, Eleanor collaborates with various teams to ensure the safety and reliability of Nexus' products. To learn more about Eleanor and her role, visit https://bit.ly/4jnXO2g